Alector

IPO

Breakthroughs come from unexpected places.

Public · South San Francisco, United States · Founded 2013 · $194.5M raised

Employees
51–200
Founded
2013
Business Model
B2B
Total Funding
$194.5M
Last Round
$133.0M Series EJul 2018
Rounds
3
Type
Public

About

Alector develops therapies to treat neurodegenerative diseases by combining advanced science and technology with expertise in human genetics, neuroscience, and immunology. Their pipeline targets toxic proteins, deficient proteins, and immune/nerve cell function to improve brain health and patient outcomes.

Summary

Alector is a Biotech company based in South San Francisco, United States, founded in 2013. It has raised $194.5M in total across 3 rounds, most recently a $133.0M Series E round in Jul 2018. Investors include Hercules Capital, OrbiMed and AbbVie Ventures.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Secondary MarketSecondary MarketOct 2025

Sign up to see all 7 rounds

Series C through Secondary Market — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Alector on Indexed.vc
<a href="https://indexed.vc/companies/alector"><img src="https://indexed.vc/api/badge/company/alector" alt="Alector on Indexed.vc" width="260" height="76" /></a>